Navigation Links
FDA Approves First Generic Tamsulosin to Treat Enlarged Prostate Gland
Date:3/2/2010

Condition known as benign prostatic hyperplasia common in older men

SILVER SPRING, Md., March 2 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the first generic version of Flomax Capsules 0.4 mg (tamsulosin hydrochloride) to treat benign prostatic hyperplasia (BPH), a condition in which an enlarged prostate gland causes problems with urination.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

The most common symptoms of BPH include a weak stream during urination, urgency, leaking or dribbling, as well as more frequent urination, especially at night.

BPH is common among older men. According to the National Institutes of Health, it rarely causes symptoms before age 40, but more than half of men in their 60s and as many as 90 percent of men older than 70 have BPH symptoms.

"The approval of generic tamsulosin offers greater access to a widely used treatment for BPH," said Gary Buehler, director of the FDA's Office of Generic Drugs. "FDA is committed to making generic drugs available to patients and these drugs meet the same rigid standards as the brand name drugs."

The prescribing information and safety warnings for the generic version of tamsulosin are the same as those for Flomax Capsules. Generic tamsulosin capsules are manufactured by IMPAX Laboratories Inc. of Haywood, Calif. Information about the marketing and availability of this generic drug can be obtained from the manufacturer.

For more information

Consumer Information: Generic Drugs

http://www.fda.gov/Drugs/ResourcesForYou/ucm167906.htm

What BPH Means to Men – A Healthy Moments Podcast from the National Institutes of Health

http://www2.niddk.nih.gov/HealthEducation/HealthyMoments/04_06_2009.htm

Information on specific drug products, Drugs@FDA

http://www.accessdata.fda.gov/scripts/cder/drugsatfda/

Media Inquiries: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

Back to top

RELATED LINKS
http://www.fda.gov/

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves First New Inhaled Antibiotic for CF in More Than a Decade
2. FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinsons Disease
3. FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
4. FDA Approves Xiaflex for Debilitating Hand Condition
5. FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures
6. Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril
7. FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
8. FDA Approves a High Dose Seasonal Influenza Vaccine Specifically Intended for People Ages 65 and Older
9. FDA Approves Lillys ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
10. FDA Approves Lillys Zyprexa for Two Adolescent Indications
11. US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 Report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... estimates and forecasts are provided for the period 2015 through ... markets. Market data and analytics are derived from primary and ...
(Date:2/24/2017)... Australia , Feb. 23, 2017  Directors from Pharma To ... two companies have joined forces, resulting in the founding of Pharma ... Pharma To Market are pleased to announce their expansion ... office in Singapore . The company are delighted ... as Co-Director of the Singapore based entity. ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... USD 330.6 million by 2021 from USD 275.9 ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... industries, increasing spending on pharmaceutical R&D, and growth ... factors driving the market growth for particle counters. ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... a clinician-based audience, will be participating in Rare Disease Day events, hosted by ... In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... leadership , media relations, content marketing, social media management, corporate communications, SEO and ... in the state and in nearby New Hampshire, Massachusetts and Canada, Rosica will ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing LLC announces ... and explore the world from different perspectives. By providing a place for people ... understanding, increase empathy, and find greater happiness. , "Our approach to structuring ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for Autism and ... for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. ... to see films in an environment that accommodates their unique needs. , Launched ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the Blüm ... in children aged 3-8 with Autism, is now enrolling at three new sites. These ... the United States. , “There are currently no approved drugs that address the ...
Breaking Medicine News(10 mins):